MD MBA - Accolade Chief Delivery
| ACCD Stock | USD 3.80 0.10 2.70% |
Executive
MD MBA is Chief Delivery of Accolade
| Address | 1201 Third Avenue, Seattle, WA, United States, 98101 |
| Phone | 206 926 8100 |
| Web | https://www.accolade.com |
Accolade Management Efficiency
The company has return on total asset (ROA) of (0.0727) % which means that it has lost $0.0727 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1861) %, meaning that it created substantial loss on money invested by shareholders. Accolade's management efficiency ratios could be used to measure how well Accolade manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.18. At present, Accolade's Debt To Assets are projected to slightly decrease based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.89, whereas Net Tangible Assets are projected to grow to (249.7 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Amanda Flanders | Health Catalyst | N/A | |
| Kharen Hauck | Phreesia | N/A | |
| Evan CFA | R1 RCM Inc | N/A | |
| Maureen McKinney | Phreesia | N/A | |
| Michael Jarjour | CareMax | N/A | |
| Benjamin Landry | Health Catalyst | 42 | |
| Andrew Brailo | Premier | 53 | |
| Kevin OHara | HealthStream | 54 | |
| Robert Borchert | Privia Health Group | N/A | |
| Megan Charko | National Research Corp | N/A | |
| Linda Llewelyn | Health Catalyst | 57 | |
| Ryan Barry | Health Catalyst | N/A | |
| Rona Anhalt | Certara | 59 | |
| Pamela Spikner | R1 RCM Inc | 47 | |
| Crystal Climer | Premier | N/A | |
| Ram Sharma | Definitive Healthcare Corp | N/A | |
| Matt Ruderman | Definitive Healthcare Corp | N/A | |
| Michael JD | HealthStream | 48 | |
| Tarah Bryan | Health Catalyst | N/A | |
| Jason Hahn | National Research Corp | 52 | |
| Jessica White | Evolent Health | N/A | |
Management Performance
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0727 |
Accolade Leadership Team
Elected by the shareholders, the Accolade's board of directors comprises two types of representatives: Accolade inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Accolade. The board's role is to monitor Accolade's management team and ensure that shareholders' interests are well served. Accolade's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Accolade's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cavanaugh, President | ||
| Michael Hilton, Chief Officer | ||
| James MD, Senior Officer | ||
| Kristin Herrera, Executive Business | ||
| Colin McHugh, Chief Officer | ||
| Jennifer Hanson, Executive Officer | ||
| Richard JD, General VP | ||
| Kristen Weeks, Corp Strategy | ||
| MD MBA, Chief Delivery | ||
| Kelsi Harris, Chief President | ||
| Stephen CPA, CFO Treasurer | ||
| Kristen Bruzek, Senior Operations | ||
| Drew Garner, Executive Engineering | ||
| Richard Eskew, General VP | ||
| Carolina Lobo, Chief Officer | ||
| Todd Clardy, Ex Bus | ||
| Rajeev Singh, Chairman CEO | ||
| Todd Friedman, Senior Relations |
Accolade Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Accolade a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0727 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 302.45 M | ||||
| Shares Outstanding | 80.54 M | ||||
| Shares Owned By Insiders | 3.00 % | ||||
| Shares Owned By Institutions | 83.51 % | ||||
| Number Of Shares Shorted | 4.86 M | ||||
| Price To Book | 0.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Accolade is a strong investment it is important to analyze Accolade's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Accolade's future performance. For an informed investment choice regarding Accolade Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accolade. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Accolade Stock refer to our How to Trade Accolade Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accolade. If investors know Accolade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accolade listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share 5.706 | Quarterly Revenue Growth 0.098 | Return On Assets (0.07) | Return On Equity (0.19) |
The market value of Accolade is measured differently than its book value, which is the value of Accolade that is recorded on the company's balance sheet. Investors also form their own opinion of Accolade's value that differs from its market value or its book value, called intrinsic value, which is Accolade's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accolade's market value can be influenced by many factors that don't directly affect Accolade's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accolade's value and its price as these two are different measures arrived at by different means. Investors typically determine if Accolade is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accolade's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.